Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: Recently diagnosed, drug-naïve patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. RESULTS: Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Persistent improvements were seen in those who completed 4 years of monotherapy and marked deterioration of β-cell function in those who failed to maintain adequate glucose control with initial monotherapy. CONCLUSIONS: The favorable combined changes in β-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This differential effect was largely related to the impact on β-cell function11,138.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“Further progressive deterioration of β-cell function accounts for the evolving natural history of the disease from impaired glucose tolerance to type 2 diabetes10,11.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SNEDECOR, G. W. (1939) · Soil Science · doi:10.1097/00010694-193902000-00006 · Cited by 19,359
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
Regression Diagnostics: Identifying Influential Data and Sources of Collinearity
Belsley, D. A., Kuh, E., & Welsch, R. E. (1980) · Wiley Series in Probability and Statistics · doi:10.1002/0471725153 · Cited by 7,297
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
Regression Diagnostics -- Identifying Influential Data and Sources of Collinearity
Beaumont, C. D., Belsley, D. A., Kuh, E., & Welsch, R. E. (1981) · The Journal of the Operational Research Society · doi:10.2307/2581267 · Cited by 6,359
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“This is best demonstrated by the loss of b-cell function over time in individuals who progress from states of impaired glucose metabolism to diabetes (14,15).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 1
- Faulenbach, 2008, Prevalence of negative insulinogenic index by glucose tolerance in three different cohorts, Diabetes, 57, A669
Cited by
Items 201–249 of 249
Hao, Z., Yao, J., Zhao, X., Liu, R., Chang, B., & Shao, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-41883-y · Cited by 3
The linearized disposition index augments understanding of treatment effects in diabetes
Kile, A. J., Hanna, C., Hannon, T. S., Kirkman, M. S., Considine, R. V., Patel, Y. R., & Mather, K. J. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00397.2020 · Cited by 2
Diabète de type 2 : pourquoi ne pas proposer une polythérapie antidiabétique d’emblée ?
Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30028-1 · Cited by 5
Grimes, R., Bennett, K., Hoey, H., Tilson, L., & Henman, M. C. (2016) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-016-1491-x · Cited by 2
Methods to Assess In Vivo Insulin Sensitivity and Insulin Secretion
Bonadonna, R. C., Boselli, L., Dei, A., & Trombetta, M. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_11 · Cited by 3
Patel, O., Muller, C. J. F., Joubert, E., Rosenkranz, B., Louw, J., & Awortwe, C. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.963489 · Cited by 3
Shimoda, M., Miyoshi-Takai, M., Irie, S., Tanabe, A., Obata, A., Okauchi, S., Hirukawa, H., Kimura, T., Kohara, K., Kamei, S., et al. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5856475 · Cited by 2
Abnormalities of Insulin Secretion and β‐Cell Defects in Type 2 Diabetes
Prato, S. D., Bianchi, C., & Daniele, G. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch16 · Cited by 5
Association between age at diagnosis of diabetes and ocular disease: Insights from a recent article
Liu, S.-Q., Wang, D., & Tang, C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.94846 · Cited by 2
Validation of Fat Mass Metrics in Pediatric Obesity
Lischka, J., Pixner, T., Mörwald, K., Lauth, W., Furthner, D., Weghuber, D., Gomahr, J., Thivel, D., Brandtner, H., Bergauer, M., et al. (2024) · Annals of Nutrition and Metabolism · doi:10.1159/000542029 · Cited by 2
Jiang, Y., Wu, D., Ni, Y., Liu, Y., Ren, H., Liu, S., Pan, C., Dai, J., Sun, Q., Ma, A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06596-z · Cited by 3
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 3
Incretin based therapies: Do they hold their promise?
Holst, J. J. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00186.x · Cited by 1
Glitazones Exert Multiple Effects on β-Cell Stimulus-Secretion Coupling
Düfer, M., Noack, K., Edalat, A., Krippeit‐Drews, P., & Drews, G. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081638 · Cited by 1
Beitelshees, A. L., Streeten, E. A., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Montasser, M. E., & Taylor, S. I. (2024) · Clinical and Translational Science · doi:10.1111/cts.13809 · Cited by 2
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.1.23 · Cited by 2
Type 2 Diabetes Mellitus in Youth
Srinivasan, S., & Levitsky, L. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_32 · Cited by 1
Deng, S., Li, S., Zhang, Q., Mao, X., Pan, D., Yang, X., & Huang, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4413947/v1 · Cited by 1
The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
Choi, A., & Kim, K. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0515 · Cited by 1
Sumitani, S., Morita, S., Deguchi, R., Hirai, K., Mukai, K., Utsu, Y., Miki, S., Sato, B., Nakamura, H., & Kasayama, S. (2014) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2014.41008 · Cited by 2
Meece, J. D., Pearson, T. L., & Siminerio, L. M. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714527802
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
Bellman, S. M., & Aromataris, E. (2014) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2014-1858 · Cited by 1
Treatment with Thiazolidinediones
Suvag, S., Utzschneider, K. M., & Kahn, S. E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_9
Self-citationApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Importance of glycemic control.
Shahady, E. J. (2011) · PubMed
Marathe, C. S. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Β-CELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW
Singh, K. A., K, B. D. R., & Singh, K. L. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/1204
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Metformin und Insulin schützen Betazellen von diabetischen Kindern nicht
Pampel, S. L. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1349-6
Direct Reprogramming of Human Cell Lines in vitro Towards a β-Cell Phenotype
Ryan, N. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.05.005
Estimates of beta cell function adjusted by anthropometric markers in patients with T2DM
Zhang, M., Su, Y., Li, Q., Jiang, S., & Yao, H. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13337
Kim, G. E., Hang, T., & LaRoche, A. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45103-5_23
Reduced β-cell function and risk of retinopathy: What's the connection?
Utzschneider, K. M. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108045
Tecnologías para el diagnóstico, manejo y control de los cultivos en el CITA de Aragón
Casterad, M. A., & Climente, R. I. (2007) · Vida rural
Effect of Metformin Intervention on Pancreatic β-Cell Apoptosis
Xie, D., Gao, Z., Liu, M., & Wang, D. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.3013
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Glucose control: Non-insulin therapies
(2014) · South African Family Practice · doi:10.1080/20786204.2014.10844579
(2010) · Diabetes Care · doi:10.2337/dc11-s098
Wu, X., Wang, R., Chen, J., Feng, G., Wang, X., Bai, R. N., Liang, X., Cao, B., Gong, C., Li, W., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14194 · Cited by 1
Type 2 Diabetes Mellitus in Youth
Srinivasan, S., & Levitsky, L. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_31
Early Versus Late Diagnosis of Youth‐Onset Type 2 Diabetes
Krishnan, N., Crimmins, N. A., Swertfeger, D. K., SCHAAF, L. R., & SHAH, A. S. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70116
Ekström, N. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Gfi1 : a new target for diabetes therapy
Napolitano, T. (2017) · theses.fr (ABES) · doi:10.70675/aaf52a4az6ce1z446czae57z0d918d5706d5
Prato, S. D., Heine, R. J., Manghi, F. P., Hsia, S. H., Valderas, E. G., Zeytinoglu, M., Razzoli, E., Kiljanski, J. I., Sharma, P., Knights, A. W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05602
Kahn, S. E. (2026) · Diabetes · doi:10.2337/dbi25-0024 · Cited by 1
Self-citationMcNeel, K., Bhanji, Z., Le, V., Lee, J., & Gallicano, I. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000096
Orientaciones terapéuticas actuales en la diabetes mellitus tipo 2
Osma, M. D. C. I., González, J. C., & García‐Barrado, M. J. (2013) · Actualidad en farmacología y terapéutica
Metadata
- Authors
- Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., & and the ADOPT Study Group
- Affiliations
- University of Washington (US)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- San Antonio Texas
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- King's College London (GB)
- University of Oxford (GB)
- Corresponding author
- Kahn, Steven E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1552-1560
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292330
- OpenAlex
- W2111473023
- Cited by
- 249
- References
- 25
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 21 · 2023: 20 · 2022: 11 · 2021: 17 · 2020: 21 · 2019: 11 · 2018: 19 · 2017: 21 · 2016: 19 · 2015: 10 · 2014: 24 · 2013: 18 · 2012: 15
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- rosiglitazone, metformin, glibenclamide, type 2 diabetes, beta-cell function, insulin sensitivity, oral glucose tolerance test, ADOPT trial, thiazolidinediones, sulfonylureas
- MeSH terms
- Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.